US equities
|
NVDA
$150.96
▼-2.89%
MU
$705.27
▼-1.00%
AMD
$530.14
▲+5.31%
SPCX
$143.50
▲+1.27%
AAPL
$352.45
▲+0.15%
MSFT
$508.29
▲+0.40%
AMZN
$267.74
▲+3.82%
TSLA
$383.72
▲+0.95%
NVDA
$150.96
▼-2.89%
MU
$705.27
▼-1.00%
AMD
$530.14
▲+5.31%
SPCX
$143.50
▲+1.27%
AAPL
$352.45
▲+0.15%
MSFT
$508.29
▲+0.40%
AMZN
$267.74
▲+3.82%
TSLA
$383.72
▲+0.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Latest News about Geoffrey Porges
Recent news which mentions Geoffrey Porges
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
December 23, 2021
Tickers
MRK
PFE
Tags
Reiteration
General
pharmaceuticals
From
Benzinga
Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst
November 23, 2021
Tickers
AZN
BNTX
GSK
JNJ
Tags
Analyst Color
Benzinga
AZN
From
Benzinga
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
September 27, 2021
Tickers
GSK
SNY
Tags
Benzinga
Analyst Color
Analyst Ratings
From
Benzinga
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
July 14, 2021
Tickers
AZN
FGEN
Tags
Analyst Color
FGEN
HC Wainwright
From
Benzinga